IndustryCompany release

Delcath lifts 2026 revenue guidance to $115-117M as HEPZATO KIT sales drive 70% Q3 growth

🇺🇸 Delcath Systems, Inc. (DCTH) · Mon 09 Nov 2026

The US company reported $35.1M in third-quarter revenue, a net profit of $7.0M and $104.3M in cash with no debt, and said HEPZATO is now at 33 active centres.

Delcath Systems reported third-quarter 2026 revenue of $35.1M on 9 November and raised its full-year revenue guidance to $115-117M. The company attributed the quarter's roughly 70% sales jump to demand for HEPZATO KIT.

HEPZATO KIT contributed $32.7M of the quarterly total, with CHEMOSAT making up the remaining $2.4M. Delcath posted net income of $7.0M for the period and ended it with $104.3M in cash and no debt.

HEPZATO is a liver-directed melphalan treatment approved by the US Food and Drug Administration for metastatic uveal melanoma. It is now available at 33 active treatment centres.

On the pipeline, Delcath said the first patient has been dosed in its Phase 2 DELUMA trial in HER2-negative metastatic breast cancer. The company also plans to file an investigational new drug (IND) application for cholangiocarcinoma in early 2027.

What it means for your team

  • Treatment-centre numbers (33 active sites) are a useful gauge of how quickly a locally delivered oncology product with specialised procedural requirements is being adopted.
  • Market-access teams tracking liver-directed therapies in uveal melanoma should note the upgraded revenue guidance as a signal of continued commercial uptake in the US.
  • Pharmacovigilance and clinical teams may want to watch the DELUMA trial and the planned cholangiocarcinoma IND, which would extend the melphalan delivery approach into new tumour types.

Company's press release (SEC filing): Delcath Systems, Inc. ↗

Article written by VigiEye from the official source (Delcath Systems, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →